QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Inebilizumab Pharmacovigilance Across NMOSD, IgG4-RD and Generalized Myasthenia Gravis

Test your understanding of the concepts covered by Inebilizumab: CD19 B-Cell Depletion Across NMOSD, IgG4-RD and gMG.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which set of information would provide the strongest assessment of a suspected HBV reactivation case during inebilizumab therapy?

Only the date of the most recent infusion Baseline HBV serology, HBV DNA where available, liver tests, prophylaxis and timing relative to B-cell depletion Only the patient's disease indication and age The infusion rate and premedication without virological data

Question 2 of 10 Which aggregate-analysis comparison would be most vulnerable to confounding if performed without adjustment?

Serious infections by cumulative infusion number within a single well-characterised population Infections in heavily pretreated IgG4-RD patients compared directly with treatment-naive NMOSD patients Hypogammaglobulinaemia stratified by serial IgG measurements Infusion reactions stratified by infusion number and premedication

Question 3 of 10 Which feature is most characteristic of the disease biology supporting inebilizumab use across NMOSD, IgG4-RD and antibody-positive gMG?

All three diseases primarily result from bacterial infection All three diseases involve identical target organs and clinical manifestations Pathogenic antibody responses and contributing B-cell lineages are important in each disease Each disease is caused by excessive CD19 expression alone

Question 4 of 10 Which statement best reflects the pharmacovigilance significance of hypogammaglobulinaemia during repeated inebilizumab treatment?

Any single low IgG value proves clinically significant immunodeficiency IgG values have no relevance unless an infusion reaction also occurred Magnitude, persistence and the associated infection history should be interpreted together Only IgM should be monitored because IgG is unaffected by B-cell depletion

Question 5 of 10 An anti-AChR-positive gMG patient develops fever, cough and positive influenza testing, followed by worsening bulbar weakness. Which interpretation best reflects the article's approach?

The case contains only a lack-of-efficacy event The infection and secondary disease exacerbation may both be relevant safety events The influenza result makes the weakness unrelated to pharmacovigilance The weakness should be classified solely as an infusion reaction

Question 6 of 10 Which case description provides the strongest evidence for a clinically important immunoglobulin-related safety pattern?

One mildly low IgG result with no infections and no follow-up Progressively declining IgG across treatment cycles accompanied by recurrent bacterial infections and antibiotic courses A normal IgG value immediately before the first infusion A transient headache during an infusion with stable immunoglobulin values

Question 7 of 10 Which statement best distinguishes an infusion reaction from delayed infection risk?

Both are assessed only by the symptoms reported on the infusion day Infusion reactions are usually assessed through immediate chronology, whereas infection risk may reflect prolonged B-cell depletion and downstream immune effects Delayed infections cannot be related to inebilizumab Infusion reactions are caused only by low immunoglobulin concentrations

Question 8 of 10 Which case-processing sequence best follows the article's practical assessment framework?

Assign causality first, then determine the indication and reconstruct exposure Confirm indication and antibody status, reconstruct dosing, establish immune baseline, define the event clinically, and assess confounders Code every post-infusion symptom as lack of efficacy Focus on the latest infusion only and disregard prior immunoglobulin and infection data

Question 9 of 10 Which statement best captures the regulatory and operational implication of rapidly expanding indications for inebilizumab?

A single historical label should be used for all current PV decisions The latest jurisdiction-specific product information should be verified for indications, dosing, screening, vaccination and pregnancy recommendations Indication expansion eliminates the need to record antibody status US and EU product information can always be assumed to be identical

Question 10 of 10 Why can worsening weakness in a patient with gMG not automatically be coded as lack of efficacy?

Weakness is unrelated to gMG Weakness may reflect infection, medication effects, respiratory compromise, natural fluctuation or autoimmune worsening Inebilizumab is only used for infections in gMG All gMG worsening is necessarily caused by treatment withdrawal

QPPV.com

Knowledge Assessment: Inebilizumab Pharmacovigilance Across NMOSD, IgG4-RD and Generalized Myasthenia Gravis

Cookie Settings